1
Screenings for FD among stroke patients have yielded discrepant results, likely as a result of heterogeneous or incomplete assessment.
2
Specimens yielding discrepant results were evaluated using a panel of respiratory virus PCR assays developed, characterized, and validated with clinical specimens.
3
Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.